ACAlexandre Carpentier

Alexandre Carpentier

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alexandre Carpentier has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Focal neurostimulation of propagating calcium waves in human neural cells using megahertz-range single-pulse focused ultrasound

    by Tom Aubier, Ivan M. Suarez-Castellanos, Magali Perier, Gilles Huberfeld, Alexandre Carpentier, W. Apoutou N'Djin

    Focused ultrasound (FUS) offers a promising neurostimulation technique that addresses the trade-off between invasiveness and spatial selectivity found in conventional electromagnetic-based methods. Evidence supporting its theoretical selectivity and comprehensive descriptions of the underlying biophysical mechanisms remain insufficient to ensure adequate control and safety. Based on observations of causal , focal , and propagating calcium waves in human neural cells in vitro , evoked using single-pulse megahertz-range FUS, a transdural FUS approach relying on an intracranial implant is proposed to overcome frequency limitations associated with transcranial ultrasound. Using an extended parameter space (0.7-8 MHz), calcium waves were shown to be selectively elicited by cavitation or acoustic radiation force. Cavitation, predominant at frequencies under 5 MHz, induced dispersed and unpredictable responses that could lead to cell damage. FUS radiation force however, predominant at frequencies over 5 MHz, elicited focal and predictable responses, without affecting cell viability. FUS-evoked intercellular calcium waves were shown to propagate across the surrounding neural network via intra cellular and extra cellular pathways driven by calcium amplification mechanisms. Collectively, these findings lay the foundation for developing wearable neurostimulation approaches to manage chronic neurological conditions.


  • Open Access

    Repeated blood-brain barrier opening using low-intensity pulsed ultrasound mitigates amyloid pathology

    by Michael Canney, Guillaume Bouchoux, Alexandre Carpentier, Pierre De Rossi

    Background: The delivery of large molecules to the pathological brain is one of the main obstacles in the development of disease-modifying drugs. This is partly due to the presence of the blood-brain barrier (BBB), which blocks the free passage of lipophobic molecules and those larger than 400 Da. One strategy to bypass this natural barrier is to use low intensity pulsed ultrasound (LIPU) to oscillate circulating micro-sized microbubbles which then exert mechanical stress on the vessel walls. This procedure allows for temporary disruption of the BBB and enhanced local delivery of therapeutics from the blood to the brain parenchyma. In this study, the effect of repeated BBB opening on neuroinflammation in a healthy mouse model was first explored followed by the effect of repeated opening on amyloid pathology in a model for Alzheimer’s disease. Methods: A cohort of wildtype mice was used to determine the effect of a single BBB opening session mediated by ultrasound/microbubbles (US/MB) on the inflammatory profile, using RT-Q-PCR on brain extracts at 2-, 4-, 8- and 15-days post opening. A second cohort of ARTE10 mice, a mouse model for amyloid pathology, was treated with a different sequence of repeated US/MB mediated BBB opening to explore the effect on the pathology. Tissues were also analyzed for immune cell infiltration, microglia and astrocyte activation, and inflammatory response. Results: Our results demonstrate that the opening of the BBB leads to a mild inflammatory response in wild-type animals. However, repeated opening of the BBB in the ARTE10 model resulted in a mild decrease in amyloid pathology, along with a mild increase of growth factor. Conclusions: Altogether, this study suggests that sonication is not only a safe method to deliver therapeutics to the brain but could also have synergistic effects in the treatment of neurodegenerative diseases.

  • Open Access

    Supplementary Figure 1 from Opening of the Blood–Brain Barrier Using Low-Intensity Pulsed Ultrasound Enhances Responses to Immunotherapy in Preclinical Glioma Models

    by Aria Sabbagh, Kevin Beccaria, Xiaoyang Ling, Anantha Marisetty, Martina Ott, Hillary Caruso, Emily Barton, Ling-Yuan Kong, Dexing Fang, Khatri Latha, et al.

    Supplement Figure 1. LIPU does not overcome immune checkpoint inhibitor resistance in a murine glioblastoma model.

  • Top Cited Papers
    Open Access

    Repeated blood–brain barrier opening with a nine-emitter implantable ultrasound device in combination with carboplatin in recurrent glioblastoma: a phase I/II clinical trial

    by Alexandre Carpentier, Roger Stupp, Adam M. Sonabend, Henry Dufour, Olivier Chinot, Bertrand Mathon, François Ducray, Jacques Guyotat, Nathalie Baize, Philippe Menei, et al.

    Here, the results of a phase 1/2 single-arm trial (NCT03744026) assessing the safety and efficacy of blood-brain barrier (BBB) disruption with an implantable ultrasound system in recurrent glioblastoma patients receiving carboplatin are reported. A nine-emitter ultrasound implant was placed at the end of tumor resection replacing the bone flap. After surgery, activation to disrupt the BBB was performed every four weeks either before or after carboplatin infusion. The primary objective of the Phase 1 was to evaluate the safety of escalating numbers of ultrasound emitters using a standard 3 + 3 dose escalation. The primary objective of the Phase 2 was to evaluate the efficacy of BBB opening using magnetic resonance imaging (MRI). The secondary objectives included safety and clinical efficacy. Thirty-three patients received a total of 90 monthly sonications with carboplatin administration and up to nine emitters activated without observed DLT. Grade 3 procedure-related adverse events consisted of pre syncope (n = 3), fatigue (n = 1), wound infection (n = 2), and pain at time of device connection (n = 7). BBB opening endpoint was met with 90% of emitters showing BBB disruption on MRI after sonication. In the 12 patients who received carboplatin just prior to sonication, the progression-free survival was 3.1 months, the 1-year overall survival rate was 58% and median overall survival was 14.0 months from surgery.


  • Open Access

    Therapeutic effects of blood‐brain barrier opening with low‐intensity pulsed ultrasounds in tau transgenic P301S mice

    by Amandine Géraudie, Maximilien Riche, Thaïs Lestra, Alexandre Carpentier, Benoit Delatour

    Background: Alzheimer’s disease is the most frequent cause of dementia. To date, almost no disease‐modifying therapeutics have proven clinical efficacy. Most of these therapeutics have targeted amyloidosis whereas tau pathology is better correlated to cognitive decline. Moreover, drugs have difficulty crossing the blood‐brain barrier (BBB) which drastically restricts their penetration into the brain parenchyma. It has been previously shown that the BBB can be safely, transiently and repeatedly opened using low‐intensity pulsed ultrasound along with microbubbles (LIPU‐MB, sonication). BBB opening with LIPU‐MB alone provides beneficial effects on amyloid burden, increase neurogenesis and modulate neuroinflammation. Our study aims at evaluating the effect of LIPU‐MB BBB opening in P301S mice model of tauopathy on tau pathology. Its secondary aims are to evaluate the effects of LIPU‐MB BBB opening on neuroinflammation, synapse density and neurogenesis.Methods: Five sessions (one per week) of LIPU‐MB were administered to wild‐type and P301S mice. Mice were sacrificed one week after the last session. Immunostaining of phosphorylated tau (AT8), microglia (Iba‐1), synapse (synaptophysin) and neurogenesis (doublecortin) were compared between the sonicated and non‐sonicated groups.Results: There was a global trend for an increase of phosphorylated tau, significant in the piriform cortex, in sonicated P301S male mice (p<.05). Interestingly, microglial densities were decreased in all brain areas in these mice (p<.0001) whereas they were increased in wild‐type mice. Tau pathology and microglial density differences between sonicated and non‐sonicated animals did not appear anymore in P301S female mice. Synapse density and neurogenesis in the hippocampus did not appear to be affected by sonication in P301S mice.Conclusion: Our results show that LIPU‐MB BBB opening decreases microglial cells loads in P301S male mice and concomitantly may impact tangles pathology. They also underline that the effects of transient BBB opening may be both sex‐ and genotype‐dependent. These results could have therapeutical impact for Alzheimer’s disease but need to be confirmed in larger cohorts of mice.

  • Open Access

    Effects of Low-Intensity Pulsed Ultrasound-Induced Blood–Brain Barrier Opening in P301S Mice Modeling Alzheimer’s Disease Tauopathies

    by Amandine Géraudie, Maximilien Riche, Thaïs Lestra, Alexandre Trotier, Léo Dupuis, Bertrand Mathon, Alexandre Carpentier, Benoît Delatour

    Alzheimer’s disease (AD) is the leading cause of dementia. No treatments have led to clinically meaningful impacts. A major obstacle for peripherally administered therapeutics targeting the central nervous system is related to the blood–brain barrier (BBB). Ultrasounds associated with microbubbles have been shown to transiently and safely open the BBB. In AD mouse models, the sole BBB opening with no adjunct drugs may be sufficient to reduce lesions and mitigate cognitive decline. However, these therapeutic effects are for now mainly assessed in preclinical mouse models of amyloidosis and remain less documented in tau lesions. The aim of the present study was therefore to evaluate the effects of repeated BBB opening using low-intensity pulsed ultrasounds (LIPU) in tau transgenic P301S mice with two main readouts: tau-positive lesions and microglial cells. Our results show that LIPU-induced BBB opening does not decrease tau pathology and may even potentiate the accumulation of pathological tau in selected brain regions. In addition, LIPU-BBB opening in P301S mice strongly reduced microglia densities in brain parenchyma, suggesting an anti-inflammatory action. These results provide a baseline for future studies using LIPU-BBB opening, such as adjunct drug therapies, in animal models and in AD patients.


  • Open Access

    Efficacy and Safety of Low-Intensity Pulsed Ultrasound-Induced Blood–Retinal Barrier Opening in Mice

    by Alexandre Bourdin, Manon Ortoli, Remi Karadayi, Lauriane Przegralek, Florian Sennlaub, Bahram Bodaghi, Xavier Guillonneau, Alexandre Carpentier, Sara Touhami

    Systemic drugs can treat various retinal pathologies such as retinal cancers; however, their ocular diffusion may be limited by the blood–retina barrier (BRB). Sonication corresponds to the use of ultrasound (US) to increase the permeability of cell barriers including in the BRB. The objective was to study the efficacy and safety of sonication using microbubble-assisted low-intensity pulsed US in inducing a transient opening of the BRB. The eyes of C57/BL6J mice were sonicated at different acoustic pressures (0.10 to 0.50 MPa). Efficacy analyses consisted of fluorescein angiography (FA) performed at different timepoints and the size of the leaked molecules was assessed using FITC-marked dextrans. Tolerance was assessed by fundus photographs, optical coherence tomography, immunohistochemistry, RT-qPCR, and electroretinograms. Sonication at 0.15 MPa was the most suitable pressure for transient BRB permeabilization without altering the morphology or function of the retina. It did not increase the expression of inflammation or apoptosis markers in the retina, retinal pigment epithelium, or choroid. The dextran assay suggested that drugs up to 150 kDa in size can cross the BRB. Microbubble-assisted sonication at an optimized acoustic pressure of 0.15 MPa provides a non-invasive method to transiently open the BRB, increasing the retinal diffusion of systemic drugs without inducing any noticeable side-effect.


  • Open Access

    Childhood Brain Tumors: A Review of Strategies to Translate CNS Drug Delivery to Clinical Trials

    by Ruman Rahman, Miroslaw Janowski, Clare L. Killick-Cole, William G. B. Singleton, Emma Campbell, Piotr Walczak, Soumen Khatua, Lukas Faltings, Marc Symons, Julia R. Schneider, et al.

    Brain and spinal tumors affect 1 in 1000 people by 25 years of age, and have diverse histological, biological, anatomical and dissemination characteristics. A mortality of 30–40% means the majority are cured, although two-thirds have life-long disability, linked to accumulated brain injury that is acquired prior to diagnosis, and after surgery or chemo-radiotherapy. Only four drugs have been licensed globally for brain tumors in 40 years and only one for children. Most new cancer drugs in clinical trials do not cross the blood–brain barrier (BBB). Techniques to enhance brain tumor drug delivery are explored in this review, and cover those that augment penetration of the BBB, and those that bypass the BBB. Developing appropriate delivery techniques could improve patient outcomes by ensuring efficacious drug exposure to tumors (including those that are drug-resistant), reducing systemic toxicities and targeting leptomeningeal metastases. Together, this drug delivery strategy seeks to enhance the efficacy of new drugs and enable re-evaluation of existing drugs that might have previously failed because of inadequate delivery. A literature review of repurposed drugs is reported, and a range of preclinical brain tumor models available for translational development are explored.


  • Open Access

    Low-Intensity Pulsed Ultrasound-Mediated Blood-Brain Barrier Opening Increases Anti-Programmed Death-Ligand 1 Delivery and Efficacy in Gl261 Mouse Model

    by Mohammed H. Ahmed, Isaias Hernández-Verdin, Emie Quissac, Nolwenn Lemaire, Coralie Guerin, Lea Guyonnet, Noël Zahr, Laura Mouton, Mathieu Santin, Alexandra Petiet, et al.

    Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood–brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the brain. We explored the safety and the efficacy of UMBO plus immune checkpoint inhibitors in preclinical models of GBM. A blood–brain barrier (BBB) opening was performed using a 1 MHz preclinical ultrasound system in combination with 10 µL/g microbubbles. Brain penetration of immune checkpoint inhibitors was determined, and immune cell populations were evaluated using flow cytometry. The impact of repeated treatments on survival was determined. In syngeneic GL261-bearing immunocompetent mice, we showed that UMBO safely and repeatedly opened the BBB. BBB opening was confirmed visually and microscopically using Evans blue dye and magnetic resonance imaging. UMBO plus anti-PDL-1 was associated with a significant improvement of overall survival compared to anti-PD-L1 alone. Using mass spectroscopy, we showed that the penetration of therapeutic antibodies can be increased when delivered intravenously compared to non-sonicated brains. Furthermore, we observed an enhancement of activated microglia percentage when combined with anti-PD-L1. Here, we report that the combination of UMBO and anti-PD-L1 dramatically increases GL261-bearing mice’s survival compared to their counterparts treated with anti-PD-L1 alone. Our study highlights the BBB as a limitation to overcome in order to increase the efficacy of anti-PD-L1 in GBM and supports clinical trials combining UMBO and in GBM patients.


  • Open Access

    Low-intensity Pulsed Ultrasound-mediated Blood-brain Barrier Opening Increases Anti-programmed Death-ligand 1 Delivery and Efficacy in Gl261 Mouse Model

    by Mohammed H Ahmed, Emie Quissac, Nolwenn Lemaire, Isaias Hernández-Verdín, Noël Zahr, Charlotte Schmitt, Guillaume Bouchoux, Michael Canney, Santin, Alexandra Petiet, et al.

    Therapeutic antibodies targeting immune checkpoints have shown limited efficacy in clinical trials in glioblastoma (GBM) patients. Ultrasound-mediated blood-brain barrier opening (UMBO) using low-intensity pulsed ultrasound improved drug delivery to the brain. We explored the safety and the efficacy of UMBO plus immune checkpoint inhibitors in preclinical models of GBM. A Blood-brain barrier (BBB) opening was performed using a 1 MHz preclinical ultrasound system in combination with 10µl/g microbubbles. Brain penetration of immune checkpoint inhibitors was determined, and immune cell populations were evaluated using flow cytometry. The impact of repeated treatments on survival was determined. In syngeneic GL261-bearing immunocompetent mice, we showed that UMBO safely and repeatedly open the BBB. BBB opening was confirmed visually and microscopically using Evans’s blue dye and magnetic resonance imaging. UMBO plus anti-PDL-1 was associated with a significant improvement of the overall survival compared to anti-PD-L1 alone. Using mass spectroscopy, we showed that the penetration of therapeutic antibodies can be increased when delivered intravenously compared to non-sonicated brains. Furthermore, we observed an enhancement of activated microglia percentage when combined with anti-PD-L1. Here, we report that the combination of UMBO and anti-PD-L1 dramatically increases GL261-bearing mice's survival compared to their counterparts treated with anti-PD-L1 alone. Our study highlights the BBB as a limitation to overcome to increase the efficacy of anti-PD-L1 in GBM and supports clinical trials combining UMBO and in GBM patients.